Resumen: The dimer [{(η6-p-cymene)RuCl}2(μ-Cl)2] (cymene=MeC6H4iPr) reacts with N,N′-bis(p-tolyl)-N′′-(2-pyridinylmethyl)guanidine (H2L1) and N,N′-bis(p-tolyl)-N′′-(2-diphenylphosphanoethyl)guanidine (H2L2), in the presence of NaSbF6, giving rise to chlorido compounds of formula [(η6-p-cymene)RuCl(H2L)][SbF6] (H2L=H2L1 (1), H2L2 (2)) in which the guanidine ligand adopts a κ2 chelate coordination mode. The related ligand (S)-N,N′-bis(p-tolyl)-N′′-(1-isopropyl, 2-diphenylphosphano ethyl)guanidine (H2L3) affords mixtures of the corresponding chlorido compound [(η6-p-cymene)RuCl(H2L3)][SbF6] (3) together with the complexes [(η6-p-cymene)RuCl2(H3L3)][SbF6] (4) and [(η6-p-cymene)Ru(κ3N,N′,P-HL3)][SbF6] (10) which contain phosphano-guanidinium and phosphano-guanidinate ions acting as monodentate and tridentate ligand, respectively. Compounds 1, 2 and mixture of 3/4/10 react with AgSbF6 rendering the cationic aqua-complexes [(η6-p-cymene)Ru(H2L)(OH2)][SbF6]2 (H2L=H2L1 (5), H2L2 (6), H2L3 (7)). These aqua-complexes exhibit a temperature-dependent fluxional process in solution. Experimental NMR studies and DFT theoretical calculations on complex 6 suggest that the process involves the exchange between two rotamers around one of the C−N guanidine bonds. Treatment of 5–7 with NaHCO3 renders the complexes [(η6-p-cymene)Ru(κ3N,N′,N′′-HL1)][SbF6] (8) and [(η6-p-cymene)Ru(κ3N,N′,P-HL)][SbF6] (HL=HL2 (9), HL3 (10)), respectively, in which the HL ligand adopts a fac κ3 coordination mode. The new complexes have been characterized by analytical and spectroscopic means, including the determination of the crystal structures of the compounds 1, 2, 5, 9 and 10, by X-ray diffractometric methods. Idioma: Inglés DOI: 10.1002/hlca.202100044 Año: 2021 Publicado en: HELVETICA CHIMICA ACTA 104, 6 (2021), e2100044 [17 pp.] ISSN: 0018-019X Factor impacto JCR: 2.201 (2021) Categ. JCR: CHEMISTRY, MULTIDISCIPLINARY rank: 122 / 180 = 0.678 (2021) - Q3 - T3 Factor impacto CITESCORE: 3.4 - Biochemistry, Genetics and Molecular Biology (Q3) - Chemical Engineering (Q3) - Pharmacology, Toxicology and Pharmaceutics (Q3)